D-dimer and fibrinogen indicate ischemic risk in patients with atrial fibrillation after percutaneous coronary intervention

被引:2
|
作者
Gjermeni, Diona [1 ]
Anfang, Viktoria [1 ]
Szabo, Sofia [1 ]
Vetter, Hannah [1 ]
Venhoff, Ana C. [2 ]
Leggewie, Stefan [1 ]
Hesselbarth, David [1 ]
Trenk, Dietmar [1 ]
Buechsel, Martin [3 ]
Westermann, Dirk [1 ]
Olivier, Christoph B. [1 ]
机构
[1] Univ Freiburg, Univ Heart Ctr Freiburg Bad Krozingen, Fac Med, Dept Cardiol & Angiol, Freiburg, Germany
[2] Univ Freiburg, Fac Med, Med Ctr, Dept Rheumatol & Clin Immunol, Freiburg, Germany
[3] Univ Freiburg, Fac Med, Med Ctr, Inst Clin Chem & Lab Med, Freiburg, Germany
来源
THROMBOSIS JOURNAL | 2024年 / 22卷 / 01期
关键词
Atrial fibrillation; Percutaneous coronary intervention; Coagulation markers; Antiphospholipid antibodies; d-dimer; Fibrinogen; Prothrombin fragments 1 and 2; ANTIPHOSPHOLIPID SYNDROME; CLASSIFICATION CRITERIA; CARDIOVASCULAR EVENTS; CHA(2)DS(2)-VASC; STROKE; DEFINITION; BIOMARKERS; ANTIBODIES; MANAGEMENT; DIAGNOSIS;
D O I
10.1186/s12959-024-00610-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background This study aimed to evaluate the association of antiphospholipid antibodies (aPL) and conventional markers of coagulation with ischemic and bleeding risk in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI).Methods In this prospective two-center observational cohort study, patients with AF and an indication for oral anticoagulation (OAC) were enrolled after PCI. Blood was drawn on day 1-3 after PCI. Dilute Russell's viper venom time was used to determine lupus anticoagulant (LA) in OAC-free plasma. Anti-cardiolipin (aCL) IgG, IgM, and anti-beta 2-Glycoprotein 1 (a beta 2GP1) IgG were analyzed by enzyme-linked immunosorbent assay (ELISA). Fibrinogen (FIB), d-dimer, and prothrombin fragment 1 and 2 (PF 1 + 2) were measured in citrated plasma. The primary ischemic outcome was time to major adverse cardiovascular events (MACE; death, myocardial infarction, or stroke) assessed at 6 months. Bleeding was defined according to International Society on Thrombosis and Haemostasis.Results 158 patients were enrolled between May 2020 and May 2021 on day 1-3 after PCI. The median age was 78 years (interquartile range [IQR] 72-82), 111 (70%) were male, and 39 (25%) presented with acute coronary syndrome. D-dimer was elevated in 74 (47%) patients, FIB was increased in 40 (25%) and PF1 + 2 in 68 (43%) patients. 32 (20%) patients had >= 1 antiphospholipid antibody elevated (aPL; LA: 19 [12%], aCL: 14 [9%], a beta 2GP1: 2 [1%]). The presence of aPL was neither significantly associated with MACE (HR 1.46, 95% CI [0.39-5.49], p = 0.579), nor bleeding (HR 1.07 [0.30-3.84], p = 0.917). Elevated d-dimer was significantly associated with higher risk for MACE (HR 5.06 [1.09-23.41], p = 0.038) and major bleeding (HR 7.04 [1.58-31.47], p = 0.011). Elevated D-dimer increased the predictive capacity of HAS-BLED for major bleedings (HAS-BLED: AUC 0.71 [0.60-0.83] vs. HAS-BLED + d-dimer: AUC 0.79 [0.70-0.88]; p = 0.025). Increased levels of FIB were associated with higher risk for MACE (HR 3.65 [1.11-11.96], p = 0.033).Conclusion Biomarkers of coagulation might be suitable to assess ischemic and bleeding risk in patients with AF following PCI.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] D-dimer as a thrombus biomarker for predicting 2-year mortality after percutaneous coronary intervention
    Zhao, Xueyan
    Li, Jianxin
    Tang, Xiaofang
    Jiang, Lin
    Chen, Jue
    Qiao, Shubin
    Yang, Yuejin
    Gao, Runlin
    Xu, Bo
    Yuan, Jinqing
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2020, 11
  • [32] Prediction of the Individual Risk of Bleeding in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
    Sulzgruber, Patrick
    Hofer, Felix
    Kazem, Niema
    Hammer, Andreas
    Niessner, Alexander
    CARDIOVASCULAR DRUGS AND THERAPY, 2021, 35 (04) : 875 - 876
  • [33] Prediction of the Individual Risk of Bleeding in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
    Patrick Sulzgruber
    Felix Hofer
    Niema Kazem
    Andreas Hammer
    Alexander Niessner
    Cardiovascular Drugs and Therapy, 2021, 35 : 875 - 876
  • [34] Balancing the Risk of Bleeding and Stroke in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the AVIATOR Registry)
    Mennuni, Marco G.
    Halperin, Jonathan L.
    Bansilal, Sameer
    Schoos, Mikkel M.
    Theodoropoulos, Kleanthis N.
    Meelu, Omar A.
    Sartori, Samantha
    Giacoppo, Daniele
    Bernelli, Chiara
    Moreno, Pedro R.
    Krishnan, Prakash
    Baber, Usman
    Lucarelli, Carla
    Dangas, George D.
    Sharma, Samin K.
    Kini, Annapoorna S.
    Tamburino, Corrado
    Chieffo, Alaide
    Colombo, Antonio
    Presbitero, Patrizia
    Mehran, Roxana
    AMERICAN JOURNAL OF CARDIOLOGY, 2015, 116 (01): : 37 - 42
  • [35] Outcomes of Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
    Sutton, Nadia R.
    Seth, Milan
    Ruwende, Cyril
    Gurm, Hitinder S.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 68 (09) : 895 - 904
  • [36] Antithrombotic Strategies in Patients With Atrial Fibrillation and Percutaneous Coronary Intervention
    Reinstadler, Sebastian J.
    Metzler, Bernhard
    Klug, Gert
    JAMA CARDIOLOGY, 2021, 6 (02) : 240 - 241
  • [37] D-dimer blood concentrations to exclude left atrial thrombus in patients with atrial fibrillation
    Almorad, Alexandre
    Ohanyan, Anush
    Bentea, Georgiana Pintea
    Wielandts, Jean-yves
    El Haddad, Milad
    Lycke, Michelle
    O'Neill, Louisa
    Morissens, Marielle
    De Keyzer, Eva
    Nguyen, Thomas
    Anghel, Laura
    Samyn, Sophie
    Berdaoui, Brahim
    Tavernier, Rene
    Vandekerckhove, Yves
    Duytschaever, Mattias
    Verbeet, Thierry
    Knecht, Sebastien
    Rodriguez, Jose Castro
    HEART, 2021, 107 (03) : 195 - 200
  • [38] Patients with and without history of atrial fibrillation after percutaneous coronary intervention increased focus on modifiable risk factors
    Kjoelseth, A.
    Norekvaal, T. M.
    Broers, G.
    Hendriks, J. M.
    Risom, S. S.
    Rotevatn, S.
    Wentzel-Larsen, T.
    Pettersen, T. R.
    EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING, 2024, 23 : I123 - I123
  • [39] MANAGEMENT OF ATRIAL FIBRILLATION IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
    Mirra, M.
    Di Maio, M.
    Vitulano, G.
    Prota, C.
    Polito, M., V
    Poto, S.
    Pierro, L.
    Piscione, F.
    TRANSLATIONAL MEDICINE AT UNISA, 2014, 9 : 33 - 37
  • [40] Atrial fibrillation status in patients with ACS and percutaneous coronary intervention
    Iwanaga, Y.
    Nakai, M.
    Inoko, M.
    Miyamoto, Y.
    EUROPEAN HEART JOURNAL, 2023, 44